

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



天 辰 生 物

**LongBio Pharma (Suzhou) Co., Ltd.**

天辰生物醫藥(蘇州)股份有限公司

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 1779)**

**VOLUNTARY ANNOUNCEMENT  
INCLUSION IN THE STOCK LIST OF  
THE SHANGHAI-HONG KONG STOCK CONNECT AND  
THE SHENZHEN-HONG KONG STOCK CONNECT**

This announcement is made by LongBio Pharma (Suzhou) Co., Ltd. (the **“Company”**, together with its subsidiaries, the **“Group”**) on a voluntary basis to inform the shareholders (the **“Shareholders”**) and potential investors (the **“Investors”**) of the Company about the latest development of the Group.

The board (the **“Board”**) of directors (the **“Director(s)”**) of the Company is pleased to announce that, pursuant to the Notice of Adjustment of the Securities List of the Hong Kong Stock Connect under the Shanghai-Hong Kong Stock Connect (《關於滬港通下港股通標的調整的通知》) and the Announcement on Adjustment of the Securities List of the Hong Kong Stock Connect under the Shenzhen-Hong Kong Stock Connect (《關於深港通下的港股通標的證券名單調整的公告》) issued by the Shanghai Stock Exchange on September 4, 2026 and the Shenzhen Stock Exchange on September 7, 2026 respectively, the Company has been included in the list of eligible securities under each of the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs with effect from September 7, 2026. Following the inclusion of the shares of the Company (the **“Shares”**) in the lists, eligible Investors in the Chinese Mainland will have direct access to the trading of the Shares through the Shanghai Stock Exchange and the Shenzhen Stock Exchange. For details, please refer to the notices or announcements regarding the adjustments to the eligible securities of Hong Kong Stock Connect published on the official website of the Shanghai Stock Exchange (<https://www.sse.com.cn>) and the official website of the Shenzhen Stock Exchange (<https://www.szse.cn>).

The Board is of the view that the inclusion of the Shares in the trading mechanisms of the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect demonstrates the market's high recognition of the Company's investment value and growth prospects. The Company expects that the inclusion of the Shares in the list of eligible securities will help further expand the Shareholder base and attract more long-term institutional investors, enhance the trading liquidity of the Shares, lay a solid foundation for the Company's long-term development, and thereby enhance the investment value and reputation of the Company in the capital markets.

The Board would like to express its sincere gratitude to all the Shareholders, Investors, and partners for their long-term trust and support. The Company will continue to focus on in-house discovery and development of biopharmaceuticals targeting allergic and autoimmune diseases.

### **About the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect**

The Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect are mutual stock market access mechanisms between the Chinese Mainland and the Hong Kong Special Administrative Region (“**Hong Kong**”), under which the Shanghai Stock Exchange and the Shenzhen Stock Exchange have established technical connectivity with The Stock Exchange of Hong Kong Limited, respectively, to enable investors in the Chinese Mainland and Hong Kong to trade eligible securities listed on each other’s market through their local securities companies or brokers.

**This announcement is made by the Company on a voluntary basis for the reference of Investors and Shareholders only, and does not constitute any investment advice. Shareholders and Investors are advised to exercise caution when dealing in the securities of the Company.**

By Order of the Board  
**LongBio Pharma (Suzhou) Co., Ltd.**  
**Dr. Liu Heng**  
*Chairman of the Board and Executive Director*

Hong Kong, September 7, 2026

*As at the date of this announcement, the Board comprises (i) Dr. LIU Heng, Dr. SUN Bill Nai-chau and Mr. XIE Ming as executive Directors; (ii) Mr. LIN Jian, Ms. GU Qin and Dr. XUE Di as non-executive Directors; and (iii) Mr. SIU Paul Yu Hay, Mr. RUAN Tim, Mr. YANG Chun and Mr. ZHOU Guofang as independent non-executive Directors.*